The Office of Management and Budget (OMB) Jan. 30 withdrew the 340B Drug Pricing Program guidance from review. The 340B guidance was one of three documents withdrawn as a result of the memorandum issued by the administration freezing the review of all regulations and guidance [see Washington Highlights, Jan. 27].
The 340B Program, administered by the Health Resources and Services Administration (HRSA), allows certain safety net hospitals to purchase outpatient drugs at a discount from drug manufacturers and use the savings to expand care services to vulnerable populations. It is unclear if the guidance will be re-submitted for review at a later date.
The AAMC provided comments on the proposed guidance during its comment period in 2015 [see Washington Highlights, Oct. 30, 2015].